Literature DB >> 15861134

Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation.

Manel G Medina1, Maria Dolores Ledesma, Jorge E Domínguez, Miguel Medina, Delia Zafra, Francesc Alameda, Carlos G Dotti, Pilar Navarro.   

Abstract

Tissue plasminogen activator (tPA) is the main activator of plasminogen into plasmin in the brain where it may have beneficial roles but also neurotoxic effects that could be plasmin dependent or not. Little is known about the substrates and pathways that mediate plasmin-independent tPA neurotoxicity. Here we show in primary hippocampal neurons that tPA promotes a catalytic-independent activation of the extracellular regulated kinase (Erk)1/2 signal transduction pathway through the N-methyl-D-aspartate receptor, G-proteins and protein kinase C. This results in GSK3 activation in a process that requires de novo synthesis of proteins, and leads to tau aberrant phosphorylation, microtubule destabilization and apoptosis. Similar effects are produced by amyloid aggregates in a tPA-dependent manner, as demonstrated by pharmacological treatments and in wt and tPA-/- mice neurons. Consistently, in Alzheimer's disease (AD) patients' brains, high levels of tPA colocalize with amyloid-rich areas, activated Erk1/2 and phosphorylated tau. This is the first demonstration of an intracellular pathway by which tPA triggers kinase activation, tau phosphorylation and neurotoxicity, suggesting a key role for this molecule in AD pathology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15861134      PMCID: PMC1142582          DOI: 10.1038/sj.emboj.7600650

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  54 in total

Review 1.  MAP kinase pathways.

Authors:  M H Cobb
Journal:  Prog Biophys Mol Biol       Date:  1999       Impact factor: 3.667

2.  Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice.

Authors:  Y F Wang; S E Tsirka; S Strickland; P E Stieg; S G Soriano; S A Lipton
Journal:  Nat Med       Date:  1998-02       Impact factor: 53.440

3.  Neuronal degeneration and a decrease in laminin-like immunoreactivity is associated with elevated tissue-type plasminogen activator in the rat hippocampus after kainic acid injection.

Authors:  N Nagai; T Urano; A Endo; H Takahashi; Y Takada; A Takada
Journal:  Neurosci Res       Date:  1999-02       Impact factor: 3.304

4.  The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling.

Authors:  O Nicole; F Docagne; C Ali; I Margaill; P Carmeliet; E T MacKenzie; D Vivien; A Buisson
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

5.  Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine.

Authors:  K A Hajjar; L Mauri; A T Jacovina; F Zhong; U A Mirza; J C Padovan; B T Chait
Journal:  J Biol Chem       Date:  1998-04-17       Impact factor: 5.157

6.  Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin.

Authors:  Z L Chen; S Strickland
Journal:  Cell       Date:  1997-12-26       Impact factor: 41.582

7.  Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C.

Authors:  Dong Liu; Tong Cheng; Huang Guo; José A Fernández; John H Griffin; Xiaomei Song; Berislav V Zlokovic
Journal:  Nat Med       Date:  2004-10-31       Impact factor: 53.440

8.  Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase.

Authors:  M Renatus; W Bode; R Huber; J Stürzebecher; M T Stubbs
Journal:  J Med Chem       Date:  1998-12-31       Impact factor: 7.446

9.  Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice.

Authors:  N Nagai; M De Mol; H R Lijnen; P Carmeliet; D Collen
Journal:  Circulation       Date:  1999-05-11       Impact factor: 29.690

10.  Inhibition of the p44/42 MAP kinase pathway protects hippocampal neurons in a cell-culture model of seizure activity.

Authors:  B Murray; A Alessandrini; A J Cole; A G Yee; E J Furshpan
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

View more
  34 in total

1.  Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function.

Authors:  Andre L Samson; Simon T Nevin; David Croucher; Be'eri Niego; Philip B Daniel; Thomas W Weiss; Eliza Moreno; Denis Monard; Daniel A Lawrence; Robert L Medcalf
Journal:  J Neurochem       Date:  2008-09-15       Impact factor: 5.372

Review 2.  Adipokines: a link between obesity and dementia?

Authors:  Amanda J Kiliaan; Ilse A C Arnoldussen; Deborah R Gustafson
Journal:  Lancet Neurol       Date:  2014-09       Impact factor: 44.182

3.  Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity.

Authors:  J Parcq; T Bertrand; A Montagne; A F Baron; R Macrez; J M Billard; A Briens; Y Hommet; J Wu; M Yepes; H R Lijnen; P Dutar; E Anglés-Cano; D Vivien
Journal:  Cell Death Differ       Date:  2012-06-29       Impact factor: 15.828

4.  Cleavage of the NR2B subunit amino terminus of N-methyl-D-aspartate (NMDA) receptor by tissue plasminogen activator: identification of the cleavage site and characterization of ifenprodil and glycine affinities on truncated NMDA receptor.

Authors:  Kay-Siong Ng; How-Wing Leung; Peter T-H Wong; Chian-Ming Low
Journal:  J Biol Chem       Date:  2012-05-18       Impact factor: 5.157

5.  An inhibitor of serine proteases, neuroserpin, acts as a neuroprotective agent in a mouse model of neurodegenerative disease.

Authors:  Yannick Simonin; Yves Charron; Peter Sonderegger; Jean-Dominique Vassalli; Ann C Kato
Journal:  J Neurosci       Date:  2006-10-11       Impact factor: 6.167

6.  CEPO (carbamylated erythropoietin)-Fc protects hippocampal cells in culture against beta amyloid-induced apoptosis: considering Akt/GSK-3β and ERK signaling pathways.

Authors:  Etrat Hooshmandi; Maryam Moosavi; Hermann Katinger; Shima Sardab; Rasoul Ghasemi; Nader Maghsoudi
Journal:  Mol Biol Rep       Date:  2020-02-17       Impact factor: 2.316

7.  Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2.

Authors:  Elena Ortiz-Zapater; Sandra Peiró; Oriol Roda; Josep M Corominas; Susana Aguilar; Coral Ampurdanés; Francisco X Real; Pilar Navarro
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

8.  Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells.

Authors:  Mariano Hurtado; Juan José Lozano; Elisabeth Castellanos; Luis A López-Fernández; Keith Harshman; Carlos Martínez-A; Angel R Ortiz; Timothy M Thomson; Rosanna Paciucci
Journal:  Gut       Date:  2007-04-23       Impact factor: 23.059

9.  The neuroprotective effect of Klotho is mediated via regulation of members of the redox system.

Authors:  Ella Zeldich; Ci-Di Chen; Teresa A Colvin; Erin A Bove-Fenderson; Jennifer Liang; Tracey B Tucker Zhou; David A Harris; Carmela R Abraham
Journal:  J Biol Chem       Date:  2014-07-18       Impact factor: 5.157

10.  Differential regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by the cyclic-AMP system in lipopolysaccharide-stimulated rat primary astrocytes.

Authors:  Soon Young Lee; Hee Jin Kim; Woo Jong Lee; So Hyun Joo; Se-Jin Jeon; Ji Woon Kim; Hee Sun Kim; Seol-Heui Han; Jongmin Lee; Seung Hwa Park; Jae Hoon Cheong; Won-Ki Kim; Kwang Ho Ko; Chan Young Shin
Journal:  Neurochem Res       Date:  2008-05-21       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.